Floatz logo

m3814

Locally Advanced Malignant Solid Neoplasm

National Cancer Institute (NCI)Phase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

46 Active assets in the Locally Advanced Malignant Solid Neoplasm cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
City of Hope Medical Center
Phase 2BB
Pembrolizumab
Mayo Clinic
Phase 2BB
Epirubicin
Mayo Clinic
Phase 2BB
Carboplatin
Pamela Munster
Phase 2B
Alpelisib
National Cancer Institute (NCI)
Phase 2B

View all 50 →

Same molecule, other indications

m3814 is also rated in:

Advanced Solid TumorsDormant
CCC
Indicative ·
52 / 100
View asset →
Unresectable Malignant Solid NeoplasmDormant
CCC
Indicative ·
50 / 100
View asset →
Locally Advanced Unresectable Gallbladder CarcinomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →